Fundamental Analysis of NUTRIBAND INC(NASDAQ:NTRB) stock

Fundamental Rating

Overall NTRB gets a fundamental rating of 2 out of 10. We evaluated NTRB against 198 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of NTRB have multiple concerns. NTRB does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year NTRB has reported negative net income.

NTRB had a negative operating cash flow in the past year.

NTRB had negative earnings in each of the past 5 years.

In the past 5 years NTRB always reported negative operating cash flow.

1.2 Ratios

NTRB's Return On Assets of -61.99% is on the low side compared to the rest of the industry. NTRB is outperformed by 64.10% of its industry peers.

NTRB has a Return On Equity (-92.52%) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-61.99%
ROE	-92.52%
ROIC	N/A

ROA(3y)-42.33%

ROA(5y)-73.89%

ROE(3y)-49.09%

ROE(5y)-368.2%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

NTRB's Gross Margin of 38.81% is in line compared to the rest of the industry. NTRB outperforms 56.41% of its industry peers.

NTRB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	38.81%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

NTRB does not have a ROIC to compare to the WACC, probably because it is not profitable.

NTRB has less shares outstanding than it did 1 year ago.

The number of shares outstanding for NTRB has been increased compared to 5 years ago.

NTRB has a worse debt/assets ratio than last year.

2.2 Solvency

NTRB has an Altman-Z score of 0.33. This is a bad value and indicates that NTRB is not financially healthy and even has some risk of bankruptcy.

NTRB has a Altman-Z score (0.33) which is comparable to the rest of the industry.

NTRB has a Debt/Equity ratio of 0.37. This is a healthy value indicating a solid balance between debt and equity.

With a Debt to Equity ratio value of 0.37, NTRB is not doing good in the industry: 61.03% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Debt/Equity	0.37
Debt/FCF	N/A
Altman-Z	0.33

ROIC/WACCN/A

WACC9.19%

2.3 Liquidity

A Current Ratio of 2.79 indicates that NTRB has no problem at all paying its short term obligations.

The Current ratio of NTRB (2.79) is comparable to the rest of the industry.

A Quick Ratio of 2.54 indicates that NTRB has no problem at all paying its short term obligations.

NTRB has a Quick ratio (2.54) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	2.79
Quick Ratio	2.54

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 32.09% over the past year.

Looking at the last year, NTRB shows a small growth in Revenue. The Revenue has grown by 2.16% in the last year.

NTRB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 77.69% yearly.

EPS 1Y (TTM)32.09%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-57.14%

Revenue 1Y (TTM)2.16%

Revenue growth 3Y77.69%

Revenue growth 5YN/A

Revenue growth Q2Q-30.78%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y57.12%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year45.91%

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NTRB. In the last year negative earnings were reported.

Also next year NTRB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for NTRB!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

NUTRIBAND INC

NASDAQ:NTRB (5/3/2024, 7:09:22 PM)

3.49

-0.16 (-4.38%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap38.29M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-61.99%
ROE	-92.52%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	38.81%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.24

Health

		Industry Rank	Sector Rank
Debt/Equity	0.37
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	2.79
Quick Ratio	2.54
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)32.09%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y57.12%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)2.16%

Revenue growth 3Y77.69%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

NUTRIBAND INC (NTRB)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens